UCB (OTCMKTS:UCBJF) Shares Gap Down - What's Next?

Key Points

• UCB SA's stock price gapped down from $305.00 to $290.10 prior to trading on Wednesday, with a trading volume of just 4 shares.
• Wall Street analysts maintain a consensus "Buy" rating for UCB, with Deutsche Bank and Morgan Stanley reaffirming positive outlooks.
• UCB specializes in developing biopharmaceutical products for neurology and immunology diseases, including treatments for conditions like epilepsy and rheumatoid arthritis.

UCB SA (OTCMKTS:UCBJF - Get Free Report)'s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $305.00, but opened at $290.10. UCB shares last traded at $290.10, with a volume of 4 shares trading hands.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on UCBJF shares. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of UCB in a research note on Monday. Morgan Stanley reaffirmed an "overweight" rating on shares of UCB in a research report on Monday, September 8th. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy".

UCB Price Performance

The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The business's 50-day moving average is $242.74 and its two-hundred day moving average is $201.50.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.